# US 2003/0203356 A1 · RNase L activator-antisense complexes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0203356 A1
- Document ID: US20030203356A1
- Status: Published application
- Kind: A1
- Application number: 10/349,163
- Filed: 2003-01-22
- Published: 2003-10-30
- Earliest claimed: 2002-01-22
- Assignees: The Cleveland Clinic Foundation
- Inventors: Robert Silverman; Hagen Cramer; Douglas Leaman; Paul Torrence
- Web page: https://patentgrep.com/patent/US20030203356A1

## CPC

- C12N 15/1131: {against viruses}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2310/315: Phosphorothioates
- C12N 2310/3183: Diol linkers, e.g. glycols or propanediols
- C12N 2310/319: linked by 2'-5' linkages, i.e. having a free 3'-position
- C12N 2310/321: 2'-O-R Modification
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to methods of targeting RNA and is particularly useful for inhibiting infection by RNA viruses with complexes of an activator of RNase L and an oligonucleotide that is capable of binding to the genome, antigenome or mRNAs of a target RNA (e.g. a negative strand RNA virus) to specifically cleave the genomic or antigenomic RNA strand of the target RNA (e.g. the virus). The invention in one embodiment relates to a covalently linked complex of an oligonucleotide that is capable of binding to the genomic or antigenomic template RNA strand of a negative strand RNA virus and/or binding to an mRNA of a viral protein (an “antisense oligonucleotide”) coupled to an activator of RNase L. In a preferred embodiment of the present invention, the oligonucleotide component of the complex is complementary to a region of the viral genomic RNA strand characterized by repeated or consensus sequences.

## Claims

### Claim 1

A composition comprising:
an oligonucleotide, comprising at least one 2′O methyl nucleotide, in which the oligonucleotide is complementary to nucleotides of a genomic RNA strand, a terminus of the oligonucleotide being attached to a linker; and
an activator of RNase L attached to the linker.

### Claim 2 (depends on 1)

The composition as set forth in claim 1 in which the activator is selected from the group consisting of
5′sp-A2′s5′A2′s5′A2′s5′A2′ and 5′sp-A2′s5′A2′s5′A2′.

### Claim 3 (depends on 1)

The composition as set forth in claim 1 wherein the oligonucleotide is
5′(AsAsAsAAUGGGGCAAAsUsAsA)m3′
wherein s is a phosphorothioate linkage and m is a 2′-O-methyl nucleotide.

### Claim 4 (depends on 1)

The composition as set forth in claim 1 in which the genomic RNA strand comprises Respiratory Syncytial Virus (RSV).

### Claim 5 (depends on 4)

The composition as set forth in claim 4 where the RSV comprises the A2 strain.

### Claim 6 (depends on 1)

The composition as set forth in claim 1, where the nucleotides are in the conserved regions of gene-start or gene-end signals.

### Claim 7 (depends on 1)

The composition as set forth in claim 1, in which the oligonucleotide comprises one or more phospho-moieties including phosphorothioate.

### Claim 8 (depends on 1)

The composition as set forth in claim 1, in which the oligonucleotide consists of 2′ O-methyl nucleotides.

### Claim 9 (depends on 1)

The composition as set forth in claim 1 in which the oligonucleotide is complementary to that portion of the RSV genome comprising the sequence: 3′ CCCCGUUUA 5′.

### Claim 10 (depends on 8)

The composition as set forth in claim 8, in which the oligonucleotide is complementary to that portion of the RSV genome comprising the sequence: 3′ CCCCGUUUA 5′.

### Claim 11 (depends on 1)

The composition as set forth in claim 1 wherein the composition is
8 5′sp-A2′s5′A2′s5′A2′s5′A2′-p(CH2CH2O)3-p-5′-(AsAsAsAAUGGGGCAAAsUsAsA)m3′
wherein s is a phosphorothioate linkage, p is a phosphodiester linkage, 5′sp is 5′-phosphothioate, and m is a 2′-O-methyl nucleotide.

### Claim 12 (depends on 1)

The composition as set forth in claim 1 wherein the composition is
9 5′sp-A2′s5′A2′s5′A2′-p(CH2CH2O)3-p-5′-(AsAsAsAAUGGGGCAAAsUsAsA)m-3′
wherein s is a phosphorothioate linkage, p is a phosphodiester linkage, 5′sp is 5′-phosphothioate, and m is a 2′-O-methyl nucleotide.

### Claim 13

A method of inhibiting Respiratory Syncytial Viral (RSV) infection in a mammalian cell infected with RSV which comprises a step of administering an amount of a complex effective to inhibit RSV infection, where the complex includes an antisense oligonucleotide, in which the sequence of said oligonucleotide is complementary to between 15 and 20 nucleotides of a conserved region of the genomic RNA strand of a strain of a Respiratory Syncytial Virus and a terminus of the oligonucleotide is attached to a linker; and an activator of RNase L attached to the linker.

### Claim 14

A method of inhibiting Respiratory Syncytial Viral (RSV) infection in a mammalian cell infected with RSV which comprises a step of providing an amount of a complex effective to inhibit RSV infection, where the complex includes an antisense oligonucleotide, having a hydroxyl moiety at a first end, in which the sequence of said oligonucleotide is complementary to between about 15 and 20 nucleotides of a normally single stranded portion of the genomic RNA strand of a strain of a Respiratory Syncytial Virus and a terminus of the oligonucleotide is attached to a linker; an activator of RNase L attached to the linker; and a pharmaceutically acceptable, aerosolizable carrier.

### Claim 15 (depends on 13)

The method as set forth in claim 13 in which the antisense oligonucleotide is 17 5′-3′-linked nucleotides.

### Claim 16 (depends on 14)

The method as set forth in claim 14 in which the antisense oligonucleotide is 17 5′-3′-linked nucleotides.

### Claim 17

A composition to inhibit RSV infection in a mammalian cell comprising:
an effective concentration of an oligonucleotide, wherein the oligonucleotide includes at least one 2′ O-methyl modified nucleotide, is between 15 and 20 nucleotides of complementary sequence to a conserved gene-start or gene-end signal of a Respiratory Syncytial Virus genomic RNA strand and is attached to a RNase L activator by a linker; and
a pharmaceutically acceptable carrier.

### Claim 18 (depends on 17)

The composition as set forth in claim 17, further comprising a pharmaceutically acceptable, aerosolizable carrier.

### Claim 19 (depends on 18)

The composition as set forth in claim 18 where the aerosolizable carrier comprises a formulation suitable for nasal administration.

### Claim 20

A composition comprising an oligonucleotide complementary to a region of a virus RNA genome, a RNA antigenome or mRNA of a negative strand RNA virus linked to a Rnase L activator.

### Claim 21 (depends on 20)

The composition as set forth in claim 20, wherein the oligonucleotide is complementary to between about 12 to about 25 nucleotides repeated in a gene-end or gene-start signals of the virus RNA genome.

### Claim 22 (depends on 20)

The composition as set forth in claim 20, wherein the oligonucleotide is complementary to between about 10 to about 30 nucleotides of the RNA antigenome.
